Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Dividends Paid - CommonDividends Paid - CommonFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesGains from Sales and DivestituresGains from Sales and DivestituresLong-Term Debt IssuancesLong-Term Debt RepaymentsNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesSales of Property, Plant and EquipmentSales of Property, Plant and EquipmentShare-based CompensationShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Core Laboratories (CLB) Change in Accured Expenses (2022 - 2026)

Core Laboratories filings provide 5 years of Change in Accured Expenses readings, the most recent being $47000.0 for Q1 2026.

  • On a quarterly basis, Change in Accured Expenses fell 92.38% to $47000.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$3.3 million, a 192.53% decrease, with the full-year FY2025 number at -$2.7 million, down 689.35% from a year prior.
  • Change in Accured Expenses hit $47000.0 in Q1 2026 for Core Laboratories, up from -$4.5 million in the prior quarter.
  • In the past five years, Change in Accured Expenses ranged from a high of $6.6 million in Q2 2024 to a low of -$5.7 million in Q4 2022.
  • Median Change in Accured Expenses over the past 5 years was -$1.1 million (2024), compared with a mean of -$852200.0.
  • The widest YoY moves for Change in Accured Expenses: up 323.82% in 2024, down 485.0% in 2024.
  • Core Laboratories' Change in Accured Expenses stood at -$5.7 million in 2022, then soared by 162.05% to $3.5 million in 2023, then plummeted by 130.04% to -$1.1 million in 2024, then crashed by 322.89% to -$4.5 million in 2025, then skyrocketed by 101.04% to $47000.0 in 2026.
  • The last three reported values for Change in Accured Expenses were $47000.0 (Q1 2026), -$4.5 million (Q4 2025), and $2.7 million (Q3 2025) per Business Quant data.